Inhibitors of interleukin-1.beta. Converting enzyme inhibitors

US6204261A · kind A · utility

Assignee

• Vertex Pharmaceuticals Incorporated · US

Inventors

• Mark James Batchelor · Abingdon, GB
• David Bebbington · Newbury, GB
• Guy Bemis · Arlington, US
• Wolf Herman Fridman · Paris, FR
• Roger John Gillespie · Wokingham, GB
• Julian M. C. Golec · Swindon, GB
• Yong Gu · Brookline, US
• David J. Lauffer · Saline, US
• David J. Livingston · Barrington, US
• Saroop Singh Matharu · Shirley, US
• Michael D. Mullican · Needham, US
• Mark A. Murcko · Holliston, US
• Robert Murdoch · Highworth, GB
• Philip Nyce · Millbury, US
• Andrea L. C. Robidoux · Andover, US
• Michael Su · Newton, US
• M. Woods Wannamaker · Stow, US
• Keith P. Wilson · Hopkinton, US
• Robert E. Zelle · Stow, US

Key dates

• Filing date: Dec 6, 1996
• Grant date: Mar 20, 2001
• Expiry date: Dec 6, 2016

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K38/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to pyradazino[1,2-a][1,2]diazepine-1-carboxamide compounds of formula: ##STR1## which compounds are inhibitors of interleukin-1beta converting enzyme.